The following amendments have been made to the 'Block listing Interim Review' announcement released on 01 June 2020 at 07:00 under RNS No 3808O.
The "Balance of unallotted securities under scheme(s) from previous return" and "Balance under scheme(s) not yet issued/allotted at end of period" have each been amended from 6,225,000 to 9,306,779.
All other details remain unchanged. The full amended text is shown below.
The reason for this change is because the balance of unallotted securities under the block admission was historically incorrectly reduced for lapsed options.
The Company's total issued share capital remains unchanged at 245,626,926 Ordinary Shares.
Block Listing Six Monthly Return
1 June 2020
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).
Date: 1 June 2020
Name of applicant:
Futura Medical Plc
Name of scheme:
Unapproved Share Option Scheme
Unapproved Share Incentive Scheme
EMI Share Option Scheme
Period of return:
1 December 2019
31 May 2020
Balance of unallotted securities under scheme(s) from previous return:
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
Less: Number of securities issued/allotted under scheme(s) during period:
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
Number and class of securities originally admitted and the date of admission
USOS Total: 3,882,912
814,424 25 May 2011
1,202,280 8 October 2013
1,466,208 25 May 2017
400,000 30 May 2018
USIS Total: 425,000
425,000 30 November 2018
EMI Total: 7,012,088
1,520,576 25 May 2011
1,467,720 8 October 2013
1,893,792 25 May 2017
790,000 30 May 2018
1,340,000 30 November 2018
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Bidhi Bhoma/ Euan Brown
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Supriya Mathur
Tel: +44 (0) 203 922 0891
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED. MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.